Dasatinib vs. imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) who have not achieved an optimal response to 3 months of imatinib therapy: the DASCERN randomized study | Leukemia
Antidiabetic Effects of the Senolytic Agent Dasatinib - Mayo Clinic Proceedings
First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET | Journal of Nuclear Medicine
Dasatinib - Tyrosine Kinase Inhibitor for Chronic Myeloid Leukaemia (CML) - Clinical Trials Arena
Fisetin, Quercetin & Dasatinib in Clinical Trials | Dr. James Kirkland Interview Series Ep 4 - YouTube
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment - Clinical Lymphoma, Myeloma and Leukemia
Utility of Therapeutic Drug Monitoring of Imatinib, Nilotinib, and Dasatinib in Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis - Clinical Therapeutics
Dasatinib (Sprycel) - Oncology Nurse Advisor
Dasatinib | Nature Reviews Drug Discovery
![PDF] Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/40a02cde3eb975357a6d12781298237c9dc12611/6-Figure4-1.png "PDF] Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia | Semantic Scholar")
PDF] Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia | Semantic Scholar
PDF) Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia
BUY dasatinib (SPRYCEL) 70 mg/1 E.R. Squibb & Sons, L.L.C.
Dasatinib for Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clinical Trial | Power
Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance | British Journal of Cancer
Dasatinib response in acute myeloid leukemia is correlated with FLT3/ITD, PTPN11 mutations and a unique gene expression signature | Haematologica
Dasatinib - Wikipedia
Final 3-year Results of the Dasatinib Discontinuation Trial in Patients With Chronic Myeloid Leukemia Who Received Dasatinib as a Second-line Treatment - ScienceDirect
![PDF] Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/40a02cde3eb975357a6d12781298237c9dc12611/2-Figure1-1.png "PDF] Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia | Semantic Scholar")
PDF] Dasatinib - clinical trials and management of adverse events in imatinib resistant/intolerant chronic myeloid leukemia | Semantic Scholar
Dasatinib (BMS-354825) | ≥99%(HPLC) | Selleck | Src inhibitor
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) - ScienceDirect
The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia - Clinical Therapeutics
JPM | Free Full-Text | Enhanced Anticancer Activity of Nanoformulation of Dasatinib against Triple-Negative Breast Cancer | HTML
Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors - Cancer Treatment Reviews
Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial - The Lancet Haematology
Dasatinib (Sprycel) - Oncology Nurse Advisor
Low-dose dasatinib in older patients with chronic myeloid leukaemia in chronic phase (DAVLEC): a single-arm, multicentre, phase 2 trial - The Lancet Haematology
FDA Approves Dasatinib for Some Children with CML - NCI
